Literature DB >> 31486491

Long noncoding RNA NEAT1 promotes the growth of gastric cancer cells by regulating miR-497-5p/PIK3R1 axis.

T-F Xia1, J Chen, K Wu, J Zhang, Q Yan.   

Abstract

OBJECTIVE: To investigate the molecular mechanisms of long noncoding RNA (lncRNA) nuclear paraspeckle assembly transcript 1 (NEAT1) in gastric cancer (GC) development progress.
MATERIALS AND METHODS: Relative mRNA and protein expression levels were quantified by quantitative Reverse Transcription-PCR (qRT-PCR) or Western blot analysis. Cell proliferation and cell apoptosis were measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay and flow cytometry, respectively. Binding sites of miR-497-5p on NEAT1 or phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) were determined by RNA pull-down assay or dual-luciferase reporter assay. Finally, the tumorigenic role of NEAT1 in GC was assessed using a xenograft model on nude mice.
RESULTS: NEAT1 was upregulated in GC tissues, promoted proliferation, and inhibited apoptosis of GC cells. NEAT1 could directly bind to and negatively regulate miR-497-5p expression. PIK3R1 was then identified as a downstream target of miR-497-5P. In GC cell models, PIK3R1 was found to be directly negatively regulated by miR-497-5p and indirectly positively regulated by NEAT1. Finally, NEAT1 knockdown inhibited tumor growth, increased miR-497-5p expression, and decreased PIK3R1 expression in xenograft model mice compared with the negative control.
CONCLUSIONS: Functioned as an oncogene, NEAT1 promoted cell growth in GC by regulating miR-497-5p/PIK3R1 axis. These results provided valuable insights into the underlying regulation signaling in gastric cancer development, shedding light on NEAT1 a promising therapeutic target from bench to clinic.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31486491     DOI: 10.26355/eurrev_201908_18731

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

1.  Identification of long noncoding RNA TC0101441 as a novel biomarker for diagnosis and prognosis of gastric cancer.

Authors:  Weiwei Wang; Jianjun Wu
Journal:  Int J Clin Exp Pathol       Date:  2021-03-01

2.  CircHIPK3/miR-876-5p/PIK3R1 axis regulates regulation proliferation, migration, invasion, and glutaminolysis in gastric cancer cells.

Authors:  Qingchun Li; Yuan Tian; Yun Liang; Chang Li
Journal:  Cancer Cell Int       Date:  2020-08-13       Impact factor: 5.722

Review 3.  Autophagy and gastrointestinal cancers: the behind the scenes role of long non-coding RNAs in initiation, progression, and treatment resistance.

Authors:  Rana Shafabakhsh; Farzaneh Arianfar; Massoud Vosough; Hamid Reza Mirzaei; Maryam Mahjoubin-Tehran; Hashem Khanbabaei; Hamed Kowsari; Layla Shojaie; Maryam Ebadi Fard Azar; Michael R Hamblin; Hamed Mirzaei
Journal:  Cancer Gene Ther       Date:  2021-01-11       Impact factor: 5.987

4.  Silencing of miR-17-5p suppresses cell proliferation and promotes cell apoptosis by directly targeting PIK3R1 in laryngeal squamous cell carcinoma.

Authors:  Jian-Xing Wang; Xin-Ju Jia; Yan Liu; Jin-Hui Dong; Xiu-Min Ren; Ou Xu; Sheng-Hui Liu; Chun-Guang Shan
Journal:  Cancer Cell Int       Date:  2020-01-10       Impact factor: 5.722

5.  Regulatory Effect of miR497-5p-CCNE1 Axis in Triple-Negative Breast Cancer Cells and Its Predictive Value for Early Diagnosis.

Authors:  Wei-Wei Liu; Wei-Dong Li; Yan-Ju Zhang; Man-Li Zhang
Journal:  Cancer Manag Res       Date:  2021-01-18       Impact factor: 3.989

Review 6.  NEAT1 as a competing endogenous RNA in tumorigenesis of various cancers: Role, mechanism and therapeutic potential.

Authors:  Kun Li; Tongyue Yao; Yu Zhang; Wen Li; Ziqiang Wang
Journal:  Int J Biol Sci       Date:  2021-08-03       Impact factor: 6.580

7.  LncRNA LINC00662 promotes colon cancer tumor growth and metastasis by competitively binding with miR-340-5p to regulate CLDN8/IL22 co-expression and activating ERK signaling pathway.

Authors:  Bo Cheng; Aimei Rong; Quanbo Zhou; Wenlu Li
Journal:  J Exp Clin Cancer Res       Date:  2020-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.